Identification of TLR downstream pathways in stroke patients

Clinical Biochemistry

Volumn 46, Issue 12, 2013, Pages 1058-1064

  Wu, Dean ^a,b   Lee, Yuan Chii G ^b   Liu, Hsing Cheng ^c,d   Yuan, Rey Yue ^b   Chiou, Hung Yi ^b   Hung, Chia Hsiu ^b   Hu, Chaur Jong ^a,b,e  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL DEFENSE UNIVERSITY   (Taiwan)

Author keywords

Ischemic stroke; MRNA; Pathway analysis; Toll like receptors

Indexed keywords

MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN CONJUGATING ENZYME;

ARTICLE; BLOOD SAMPLING; BRAIN ISCHEMIA; CONTROLLED STUDY; EXTRACELLULAR SPACE; GENE ACTIVATION; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR BINDING; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; STROKE PATIENT; TISSUE INJURY;

ISCHEMIC STROKE; MRNA; PATHWAY ANALYSIS; TOLL-LIKE RECEPTORS;

BRAIN ISCHEMIA; CASE-CONTROL STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; PROTEOLYSIS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STROKE; TOLL-LIKE RECEPTORS; UBIQUITIN;

EID: 84880700062     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.05.059     Document Type: Article

References (32)

1. Bradley W.G. Neurology in clinical practice 2004, Butterworth-Heinemann, Philadelphia.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
3. Kiechl S., Lorenz E., Reindl M., Wiedermann C.J., Oberhollenzer F., Bonora E., et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002, 347:185-192.
4. Kopp E.B., Medzhitov R. The toll-receptor family and control of innate immunity. Curr Opin Immunol 1999, 11:13-18.
5. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
6. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001, 2:675-680.
7. Marsh B.J., Williams-Karnesky R.L., Stenzel-Poore M.P. Toll-like receptor signaling in endogenous neuroprotection and stroke. Neuroscience 2009, 158:1007-1020.
8. Xu X.H., Shah P.K., Faure E., Equils O., Thomas L., Fishbein M.C., et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001, 104(25):3103-3108.
9. Pasterkamp G., Van Keulen J.K., De Kleijn D.P. Role of toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest 2004, 34:328-334.
10. Curtiss L.K., Tobias P.S. The toll of toll-like receptors, especially toll-like receptor 2, on murine atherosclerosis. Curr Drug Targets 2007, 8:1230-1238.
11. Kristina E., Jesper S., Gran K.H., Zhong-qun Y. Expression of Toll-like receptors in human atherosclerotic lesions. Circulation 2002, 105:1158-1161.
12. Hung C.H., Wu D., Lin F.Y., Yuan R.Y., Hu C.J. Toll-like receptor 4 and vcam-1 in monocyte-endothelium adhesion induced by lipopolysaccharide. J Exp Clin Med 2010, 2:297-301.
13. Dean W., Jehn-Shing S., Hsing-Cheng L., Rey-Yue Y., Jia-Ming Y., Jau-Jiuan S., et al. Increase of toll-like receptor 4 but decreased of interleukin-8 mRNA expression among ischemic stroke patients under aspirin treatment. Clin Biochem 2012, 45(16-17):1316-1319.
14. Brea D., Blanco M., Ramos-Cabrer P., Moldes O., Arias S., Pérez-Mato M., et al. Toll-like receptors 2 and 4 in ischemic stroke: outcome and therapeutic values. J Cereb Blood Flow Metab 2011, 31(6):1424-1431.
15. Abdelsadik A., Trad A. Toll-like receptors on the fork roads between innate and adaptive immunity. Hum Immunol 2011, 72(12):1188-1193.
16. Yan K., Yingying L. Toll-like receptors in inflammation of the central nervous system. Int Immunopharmacol 2011, 11:1407-1414.
17. Douglas L.M. The emerging role of innate immunity in the heart and vascular system. For whom the cell tolls. Circ Res 2011, 108:1133-1145.
18. Sun Y.V. Integration of biological networks and pathways with genetic association studies. Hum Genet 2012, 131(10):1677-1686.
19. Kanehisa M., Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000, 28(1):27-30.
20. Kanehisa M., Goto S., Sato Y., Furumichi M., Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 2012, 40:D109-D114. [Database issue].
21. Oshiumi H., Matsumoto M., Funami K., Akazawa T., Seya T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat Immunol 2003, 4(2):161-167.
22. Sasai M., Tatematsu M., Oshuimi H., Funami K., Matsumoto M., Hatakeyama S., et al. Direct binding of TRAF2 and TRAF6 to TICAM-1/TRIF adaptor participates in activation of the Toll-like receptor 3/4 pathway. Mol Immunol 2010, 47(6):1283-1291.
23. Barr T.L., Conley Y., Ding J., Dillman A., Warach S., Singleton A., et al. Genomic biomarkers and cellular pathways of ischemic stroke by RNA gene expression profiling. Neurology 2010, 75(11):1009-1014.
24. Caso J.R., Pradillo J.M., Hurtado O., Lorenzo P., Moro M.A., Lizasoain I. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation 2007, 115:1599-1608.
25. Brea D., Blanco M., Ramos-Cabrer P., Moldes O., Arias S., Perez-Mato M., et al. Toll-like receptors 2 and 4 in ischemic stroke: outcome and therapeutic values. J Cereb Blood Flow Metab 2011, 31(6):1424-1431.
26. Famakin B.M., Mou Y., Ruetzler C.A., Bembry J., Maric D., Hallenbeck J.M. Disruption of downstream MyD88 or TRIF Toll-like receptor signaling does not protect against cerebral ischemia. Brain Res 2011, 1388:148-156.
27. Bolanle F., Yongshan M., Maria S., Modinat L., Hallenbeck J. Downstream Toll-like receptor signaling mediates adaptor-specific cytokine expression following focal cerebral ischemia. J Neuroinflammation 2012, 9:174.
28. van Wijk S.J., Timmers H.T. The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins. FASEB J 2010, 24(4):981-993.
29. Deng L., Wang C., Spencer E., Yang L., Braun A., You J., et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000, 103(2):351-361.
30. Turvey S.E., Hawn T.R. Towards subtlety: understanding the role of Toll-like receptor signaling in susceptibility to human infections. Clin Immunol 2006, 120(1):1-9.
31. Liu Z., He D., Zhang X., Li Y., Zhu C., Dong L., et al. Neuroprotective effect of early and short-time applying sophoridine in pMCAO rat brain: down-regulated TRAF6 and up-regulated p-ERK1/2 expression, ameliorated brain infaction and edema. Brain Res Bull 2012, 88(4):379-384.
32. Jakus P.B., Kalman N., Antus C., Radnai B., Tucsek Z., Gallyas F., et al. TRAF6 is functional in inhibition of TLR4-mediated NF-κB activation by resveratrol. J Nutr Biochem Aug 24 2012.